Differentiation between G3 well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma can be challenging. The distinction is based on the presence of certain features, such as high-grade cytologic atypia, solid growth pattern, necrosis, a very high Ki67 index, and certain molecular mutation profiles. Such distinctions have significant clinical implications, as neuroendocrine tumor and neuroendocrine carcinoma have different management and clinical outcomes for these diseases. Here, we report a stomach neuroendocrine carcinoma patient with ambiguous morphology and molecular alterations.
Xu et al. (Sat,) studied this question.